ArticleScience advances2015
Cystic fibrosis-adapted
Article in Science advances, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 84 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
84 citing papers in PubMed, 128 citations in OpenAlex.
- Identification of DksA as a novel pro-inflammatory mediator ofVirulence · 2026Article
- Article
- The conserved coordination of acyl-homoserine lactone and PqsE signaling defines the RhlR-dependent quorum-sensing network inbioRxiv : the preprint server for biology · 2026Article
- Exploring the Role ofACS infectious diseases · 2026Article
- Article
- Biophysical Constraints Dictate the Stability of Social Traits inbioRxiv : the preprint server for biology · 2026Article
- Exploiting Pharmacokinetic/Pharmacodynamic Methods for Optimizing and Accelerating Drug Development of Innovative Anti-Infectives.ChemMedChem · 2026Review
- Mitigating antimicrobial resistance in the animal industry: reduction strategies and alternatives to antibiotics.Frontiers in veterinary science · 2026Review
- Unraveling the immunosuppressive role of Elastase B produced by cystic fibrosis isolates ofVirulence · 2025Article
- Combination Therapy of Cefiderocol and Polymyxin B Against Pseudomonas aeruginosa Keratitis Isolates In Vitro.Translational vision science & technology · 2025Article
- Hijacking anaerobic metabolism to restore antibiotic efficacy inApplied and environmental microbiology · 2025Article
- Article
- Article
- Metabolomic profiling reveals unique markers for Pseudomonas aeruginosa LasR deficiency.Scientific reports · 2025Article
- Immune system dynamics in response to Pseudomonas aeruginosa biofilms.NPJ biofilms and microbiomes · 2025Review
- Phage-host interaction inApplied and environmental microbiology · 2025Article
- IL-6 trans-signaling in cystic fibrosis bronchial cells potentiates TNF-α-driven ICAM-1 expression.Frontiers in cell and developmental biology · 2025Article
- Palmitoleic acid inhibits Pseudomonas aeruginosa quorum sensing activation and protects lungs from infectious injury.Respiratory research · 2024Article
- Antibiofilm activity ofBiofilm · 2024Article
- Article
24 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 6 institutions in 2 countries.
Funding
Abstract
Cystic fibrosis lung disease is characterized by chronic airway infections with the opportunistic pathogen
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.